GenePath Diagnostics
Nickhil Jakatdar has a strong background in various industries, including technology, sports, and healthcare. Nickhil is currently serving as the CEO of GenePath Diagnostics since 2019. In addition, they hold the role of Advisory Board Member at both CITRIS and the Banatao Institute and the South Asian Heart Center. Jakatdar is an investor in the Oakland Roots Sports Club, an American professional soccer team, and was the first investor in Genies. Nickhil has also served as an Independent Director on the Board of Directors at KPIT. Previously, Jakatdar founded and served as CEO of Viu, a company founded in 2008 and sold in 2019. Nickhil held leadership positions at CommandCAD Inc, Praesagus, and Timbre Technologies, where they served as a founding investor, President and COO, and Founder and COO, respectively.
Nickhil Jakatdar earned a Ph.D. in EECS from the University of California, Berkeley, from 1998-2000. Prior to that, they obtained an M.S. in EECS from the same university from 1995-1998. Nickhil began their education at Savitribai Phule Pune University, where they completed their BE in Electrical Engineering from 1991-1995.
This person is not in any teams
This person is not in any offices
GenePath Diagnostics
GenePath Diagnostics is a next generation molecular genetics company that provides state-of-the-art clinical in vitro diagnostic services for developing markets and is developing novel next generation diagnostic tests and platforms for the global market. We are an innovation-centric company with a strong emphasis on continuous R&D. We are constantly evolving in pace with global developments in the field and have the ability to develop new tests where needed, e.g. to respond to an emerging pathogen or a rare genetic disorder. We pride ourselves on our ability to work with clinicians to come up with novel or custom solutions to diagnostic problems. At GenePath, we strongly believe in our culture. Our company’s values are the principles and ideals that we live by.